TOP
  • About
    • About
      • Philosophy
      • Culture
      • Transparency
      • Leadership Team
      • Partners
  • Sustainability
  • Innovation
    • Innovation
      • Investigator Research
      • Educational Grants
      • Clinical Trial Data Privacy Policy
      • Medical Writing Grants
      • Medical Information
  • News
    • News
      • News Posts
      • Media Assets
  • Products
  • Investors
  • Careers
  • Contact
United States
Worldwide
  1. HOME
  2. News

News

  1. Jan
  2. Feb
  3. Mar
  4. Apr
  5. May
  6. Jun
  7. Jul
  8. Aug
  9. Sep
  10. Oct
  11. Nov
  12. Dec

April

Apr.23, 2022 Release
New Data for Shionogi’s COVID-19 Once-Daily Oral Antiviral S-217622 Show Rapid Virus Clearance

March

Mar.16, 2022 Release
ACTG and Shionogi Announce Progress on Global Phase 3 Trial of Novel COVID-19 Oral Antiviral Agent S 217622
Mar.11, 2022 Release
Shionogi Provides Humanitarian Aid to Ukraine

February

Feb.25, 2022 Release
Shionogi Files for Approval of S-217622, a Therapeutic Drug for COVID-19, in Japan
Feb.18, 2022 Release
Shionogi Presents Phase 2/3 Clinical Trial Results (Phase 2a Part) for the COVID-19 Therapeutic Drug S-217622
  • About
  • Sustainability
  • Innovation
  • Products
  • Investors
  • News
  • Careers
  • Contact
  • YouTube別ウィンドウで開く
  • Glassdoor別ウィンドウで開く
  • LinkedIn別ウィンドウで開く
  • Worldwide
  • Privacy Policy
  • Terms of Use
© 2021 Shionogi Inc. Florham Park, NJ 07932. All Rights Reserved. 05/20